Vivaldi Capital Management LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 148.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,087 shares of the biopharmaceutical company’s stock after purchasing an additional 28,143 shares during the quarter. Vivaldi Capital Management LLC’s holdings in Pfizer were worth $2,040,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Morgan Stanley lifted its position in shares of Pfizer by 2.4% during the 2nd quarter. Morgan Stanley now owns 46,536,777 shares of the biopharmaceutical company’s stock valued at $2,015,972,000 after buying an additional 1,071,897 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its position in shares of Pfizer by 9.7% during the 2nd quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 64,821 shares of the biopharmaceutical company’s stock valued at $2,808,000 after buying an additional 5,727 shares in the last quarter. Apriem Advisors lifted its position in shares of Pfizer by 0.3% during the 2nd quarter. Apriem Advisors now owns 204,832 shares of the biopharmaceutical company’s stock valued at $8,873,000 after buying an additional 657 shares in the last quarter. Connors Investor Services Inc. lifted its position in shares of Pfizer by 15.1% during the 2nd quarter. Connors Investor Services Inc. now owns 312,843 shares of the biopharmaceutical company’s stock valued at $13,552,000 after buying an additional 41,082 shares in the last quarter. Finally, Wsfs Capital Management LLC lifted its position in shares of Pfizer by 22.2% during the 2nd quarter. Wsfs Capital Management LLC now owns 13,672 shares of the biopharmaceutical company’s stock valued at $592,000 after buying an additional 2,484 shares in the last quarter. 71.68% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE PFE traded up $0.25 during trading on Friday, hitting $36.76. 831,199 shares of the company were exchanged, compared to its average volume of 19,822,398. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The company has a fifty day moving average price of $36.04 and a 200-day moving average price of $40.59. The firm has a market capitalization of $201.88 billion, a PE ratio of 12.25, a P/E/G ratio of 2.90 and a beta of 0.65.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm earned $0.77 EPS. The company’s quarterly revenue was down 1.5% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd were issued a dividend of $0.36 per share. The ex-dividend date was Thursday, August 1st. This represents a $1.44 annualized dividend and a dividend yield of 3.92%. Pfizer’s dividend payout ratio is presently 48.00%.
A number of brokerages have recently issued reports on PFE. JPMorgan Chase & Co. increased their target price on Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a research report on Thursday. They noted that the move was a valuation call. Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. Morgan Stanley decreased their price objective on Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 27th. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, ValuEngine lowered Pfizer from a “hold” rating to a “sell” rating in a report on Saturday, September 14th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and an average target price of $45.88.
In other Pfizer news, major shareholder Pfizer Inc acquired 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, with a total value of $900,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total value of $6,753,882.56. Following the sale, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: What do I need to know about analyst ratings?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.